

Product Data Sheet

Product Name: Ansuvimab

Cat. No.: GC72368

Chemical Properties

Cas. No. 2375952-29-5

Formula

M.Wt

Solubility

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Ansuvimab

Background

Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells.

Ansuvimab blocks binding between the Ebola virus glycoprotein (GP) and the Niemann-Pick C1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

receptor by binding to the LEIKKPDGS epitope located in the receptor binding site of the GP1 subunit of GP[1].

Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) against GP-transfected target cells, with maximal activity at the concentration of 0.03 µg/mL[2].

Ansuvimab results in all macaques surviving after exposure to a lethal dose of Ebola virus in on day 0[1].

References:

[1]. Lee A, et, al. Ansuvimab: First Approval. *Drugs*. 2021 Apr;81(5):595-598.

[2]. Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potentially neutralizing antibody. *Science*. 2016 Mar 18;351(6279):1339-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA